Welcome to our dedicated page for Radiopharm Theranostics SEC filings (Ticker: RADX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Radiopharm Theranostics’ radiopharmaceutical pipeline isn’t easy—its 20-F spans hundreds of pages on trial design, radionuclide safety data, and cash-burn projections. Finding when the HEAT HER2 study reaches a dosing milestone or spotting fresh capital-raise risks can take hours. That’s why professionals searching for “Radiopharm Theranostics SEC filings explained simply” end up here.
Stock Titan’s AI reads every 10-K-equivalent, 10-Q, 8-K and S-1 the moment EDGAR releases them, then serves plain-English summaries, key-metric dashboards, and instant alerts. Instead of wading through technical appendices, you’ll see R&D spend trends, partnership revenue splits, and Radiopharm Theranostics insider trading Form 4 transactions within seconds. Our engine cross-links trial disclosures to risk factors, so understanding Radiopharm Theranostics SEC documents with AI becomes straightforward.
- Radiopharm Theranostics quarterly earnings report 10-Q filing
- Radiopharm Theranostics Form 4 insider transactions real-time
- Radiopharm Theranostics earnings report filing analysis
- Radiopharm Theranostics executive stock transactions Form 4
- Radiopharm Theranostics annual report 10-K simplified
- Radiopharm Theranostics proxy statement executive compensation
- Radiopharm Theranostics 8-K material events explained
Use these insights to monitor when insiders accumulate shares before pivotal data, verify cash runway ahead of Phase 2 expenses, or review how new collaborations shift revenue potential. Whether you’re a biotech portfolio manager or a sell-side analyst, Stock Titan turns raw filings into actionable intelligence, so you can focus on what really moves Radiopharm’s valuation.
Radiopharm Theranostics Limited (RDPTF) reported a challenging year ending June 30, 2025, with a total comprehensive loss of A$37.88 million and negative operating cash flows of approximately A$36.65 million. The group recorded accumulated losses of A$145.73 million and significant research and development investment, including R&D expenses of A$27.52 million (line item) and intangible assets on the balance sheet of A$49.09 million.
The company generated other income including an R&D tax incentive (A$9.37 million recognised) and raised cash from financing activities (A$45.43 million reported in one table). Key governance and management details are disclosed, including CEO Riccardo Canevari and a Board with named directors and option/share holdings. The filing also discloses material contingent consideration balances, significant finance expenses and assumptions used in impairment and contingent consideration models.
FAQ
What is the current stock price of Radiopharm Theranostics (RADX)?
What is the market cap of Radiopharm Theranostics (RADX)?
